Ly-2127399

Known as: LY2127399, LY3022859 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
LY3022859 is an anti-TGFβRII IgG1 monoclonal antibody that inhibits receptor-mediated signaling activation. The primary objective… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2016
2016
B-cell activating factor (BAFF) promotes the survival and adhesion of multiple myeloma (MM) cells. Tabalumab (LY2127399) is an… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2015
Review
2015
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) comprises several clinical entities with diverse clinical… (More)
  • figure 1
  • table 1
  • table 2
  • table 4
Is this relevant?
Review
2012
Review
2012
For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment… (More)
  • figure 1
  • table 1
Is this relevant?
2011
2011
8012 Background: LY2127399 (LY) is a human mAb that neutralizes membrane-bound and soluble B cell activating factor (BAFF). LY… (More)
Is this relevant?
Review
2011
Review
2011
Myeloma bone disease (BD) not only impairs quality of life, but is also associated with impaired survival. Studies of the biology… (More)
  • figure 1
Is this relevant?
Review
2010
Review
2010
Treating multiple sclerosis (MS) with monoclonal antibodies (mAbs) has been marked by both progress and setbacks in the past 2… (More)
Is this relevant?
Review
2010
Review
2010
The third part of this in-depth review series on the treatment of multiple sclerosis (MS) with monoclonal antibodies covers the… (More)
  • figure 1
  • figure 2
Is this relevant?